Questioning the Safety and Benefits of Evolocumab – Authors' Reply

The Lancet Diabetes and Endocrinology - Netherlands
doi 10.1016/s2213-8587(17)30403-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy